• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    All News #Library
    Biotech

    Kymera Therapeutics To Release Q1 2026 Financial Results

    GLOBENEWSWIRE

    Kymera Pharma`s KT-621, Granted FDA Fast Track For Severe Asthma

    GLOBENEWSWIRE

    Kymera Announces Gilead’ Option Exercise to License KT-200

    ENDPOINTS NEWS

    Gilead Pays Kymera $45M For Preclinical Protein Degrader

    FIERCE BIOTECH

    Kymera Therapeutics Presents KT-621 Broaden Data at AAD

    GLOBENEWSWIRE

    Kymera`s Late-Breaking Oral Presentation on KT-621 at AAD Meeting

    GLOBENEWSWIRE

    Kymera Therapeutics Joins March Investor Conferences

    GLOBENEWSWIRE

    Kymera Therapeutics Reports Q4 & FY 2025 Financial Results

    GLOBENEWSWIRE

    Kymera Doses First Patient in BREADTH KT-621 Trial

    GLOBENEWSWIRE

    FDA Grants Fast Track to Kymera`s KT-621 for Atopic Dermatitis

    GLOBENEWSWIRE

    Kymera Closes $602M Offering With Full Option Exercise

    GLOBENEWSWIRE

    Kymera Reports Positive Results In KT-621, Phase 1B Trial

    GLOBENEWSWIRE

    Kymera Therapeutics Announces Proposed Public Offering

    GLOBENEWSWIRE

    Kymera Unveils KT-621 BroADen Ph1b Atopic Dermatitis Results

    GLOBENEWSWIRE

    Kymera Launches BROADEN-2 Phase 2b Trial for Atopic Dermatitis

    GLOBENEWSWIRE

    Kymera Therapeutics Joins December Investor Conferences

    GLOBENEWSWIRE

    Kymera Therapeutics to Release Q3 2025 Financial Results on Nov 4

    GLOBENEWSWIRE

    Kymera Unveils Preclinical Data on KT-579, at ACR Meeting

    GLOBENEWSWIRE

    Kymera Announces Late-Breaking Oral Presentations on KT-621

    GLOBENEWSWIRE

    Gilead Signs up to $750 Million Cancer Drug Deal with Kymera

    PRESS RELEASE

    Kymera Therapeutics: 1st Patient Dosed in Ph 1b Atopic Dermatitis

    GLOBENEWSWIRE

    NEOsphere, Kymera Collaborate on Novel Molecular Glue Target Discovery

    BIOTECHNEWSWIRE

    R&D Day Highlights Kymera™s Immunology Strategy and Emerging Pipeline

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.